贝派地酸在有和无糖尿病患者中的疗效与安全性:CLEAR Outcomes 随机试验的预设分析
CLEAR Outcomes 试验的预设分析纳入 13970 例他汀不耐受高心血管风险患者,其中糖尿病 6373 例、糖尿病前期 5796 例、血糖正常 1801 例。中位随访 3.4 年,糖尿病患者接受贝派地酸后 MACE-4 风险低于安慰剂(HR 0.83;95%CI 0.72-0.95;绝对风险降低 2.4%),无糖尿病者新发糖尿病和 HbA1c 与安慰剂相似。
要点
- 糖尿病患者用贝派地酸降低 MACE-4 风险:HR 0.83;95%CI 0.72-0.95;绝对风险降低 2.4%。
- 贝派地酸组新发糖尿病 11.1% vs 安慰剂组 11.5%(HR 0.95;95%CI 0.83-1.09)。
- 糖尿病前期和血糖正常者 HbA1c 在 12 个月和试验结束时两组相似。
核心结论
- 糖尿病患者使用贝派地酸可降低 LDL 胆固醇、高敏 C 反应蛋白和心血管事件风险。
- 无糖尿病患者使用贝派地酸未增加新发糖尿病或使 HbA1c 恶化。
- 贝派地酸的疗效和心血管代谢安全性使其成为有和无糖尿病者的临床选择。
研究设计与样本
- CLEAR Outcomes 为随机、双盲、安慰剂对照试验,在 32 个国家 1250 个初级保健和门诊中心开展。
- 纳入不愿或不能服用指南推荐剂量他汀且 LDL 胆固醇≥2.59 mmol/L 的患者,1:1 随机接受贝派地酸 180 mg 每日一次或安慰剂。
- 本预设分析按基线血糖状态分层,在意向治疗人群中分析四组分主要不良心血管事件(MACE-4)。
- 新发糖尿病和 HbA1c 升高的预设分析在基线无糖尿病患者中评估。
- 2016年12月22日至2022年11月7日筛查并随机分配 13970 例患者,糖尿病 6373 例(45.6%)、糖尿病前期 5796 例(41.5%)、血糖正常 1801 例(12.9%)。
主要发现
- 中位随访 3.4 年,糖尿病患者贝派地酸组 MACE-4 风险低于安慰剂组(HR 0.83;95%CI 0.72-0.95;绝对风险降低 2.4%),血糖分层间无效应修饰的统计学证据(交互作用 p=0.42)。
- 新发糖尿病比例贝派地酸组 429/3848(11.1%)vs 安慰剂组 433/3749(11.5%)(HR 0.95;95%CI 0.83-1.09)。
- 糖尿病前期和血糖正常者中,12 个月和试验结束时 HbA1c 浓度两组相似。
- 贝派地酸组 6 个月时安慰剂校正的 LDL 胆固醇和高敏 C 反应蛋白在各血糖分层(糖尿病、糖尿病前期、血糖正常)均降低(均 p<0.001)。
关键数值与推荐
- 糖尿病患者贝派地酸组 MACE-4 的 HR 0.83(95%CI 0.72-0.95),绝对风险降低 2.4%。
- 新发糖尿病贝派地酸组 11.1% vs 安慰剂组 11.5%,HR 0.95(95%CI 0.83-1.09)。
- 血糖分层间交互作用 p=0.42。
- 6 个月安慰剂校正的 LDL 胆固醇和高敏 C 反应蛋白在各血糖分层均降低,均 p<0.001。
临床怎么用
- 作者认为,贝派地酸的疗效和心血管代谢安全性使其成为有和无糖尿病者的临床选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins reduce LDL cholesterol and cardiovascular events among those with or without diabetes but have been reported to increase new-onset diabetes. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the risk of major adverse cardiovascular events among statin-intolerant patients at high cardiovascular risk. In this prespecified analysis, our dual aims were to evaluate the cardiovascular benefits of bempedoic acid, an ATP-citrate lyase inhibitor, in individuals with diabetes, and to evaluate the risk of new-onset diabetes and HbA1c among those without diabetes in the CLEAR Outcomes trial. METHODS: CLEAR Outcomes was a randomised, double-blind, placebo-controlled trial conducted across 1250 primary care and outpatient sites in 32 countries. Patients with or without cardiovascular disease who were unwilling or unable to take guideline-recommended doses of statins and an LDL cholesterol of 2·59 mmol/L or more were randomly assigned (1:1) in a double-blinded manner to either bempedoic acid 180 mg once per day or placebo. In this prespecified analysis, the efficacy endpoint was a time-to-event analysis of four-component major adverse cardiovascular event (MACE-4), which is the composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularisation, using the intention-to-treat population stratified by baseline glycaemia status. The prespecified analysis of risk of new-onset diabetes and HbA1c increase was evaluated in patients without diabetes at baseline. The CLEAR Outcomes trial was completed on Nov 7, 2022, and is registered with ClinicalTrials.gov (NCT02993406). FINDINGS: Between Dec 22, 2016, and Nov 7, 2022, 13 970 patients were screened and randomly assigned; 6373 (45·6%) with diabetes, 5796 (41·5%) with prediabetes, and 1801 (12·9%) with normoglycaemia. Over a median of 3·4 years follow up, patients with diabetes had significant relative and absolute cardiovascular risk reductions in MACE-4 endpoints with bempedoic acid (HR 0·83; 95% CI 0·72-0·95; absolute risk reduction of 2·4%) compared to placebo, with no statistical evidence of effect modification across glycaemic strata (interaction p=0·42). The proportion of patients who developed new-onset diabetes were similar between the bempedoic acid and placebo groups, with 429 of 3848 (11·1%) with bempedoic acid versus 433 of 3749 (11·5%) with placebo (HR 0·95; 95% CI 0·83-1·09). HbA1c concentrations at month 12 and the end of the study were similar between randomised groups in patients who had prediabetes and normoglycaemia. Placebo-corrected LDL cholesterol concentrations and high-sensitivity C-reactive protein at 6 months were reduced in each glycaemic stratum (diabetes, prediabtes, and normoglycaemia) for patients randomly assigned to bempedoic acid (all p<0·001). INTERPRETATION: Among patients with diabetes, bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and risk of cardiovascular events. Patients without diabetes had no increase in new-onset diabetes or worsening HbA1c with bempedoic acid. The efficacy and cardiometabolic safety profile of bempedoic acid makes it a clinical option for those with and without diabetes. FUNDING: Esperion Therapeutics.
引用
- Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2023. PMID: 38061370. doi:10.1016/S2213-8587(23)00316-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。